New drug combo targets hard-to-treat lung cancer mutation

NCT ID NCT05074810

Ongoing Disease control Sponsor: Verastem, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two or three drugs can help people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C). The drugs aim to block cancer growth signals. About 153 adults who have or haven't received prior KRAS-targeting therapy will take part. The goal is to see if the combination shrinks tumors and is safe, but ongoing treatment is needed to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KRAS ACTIVATING MUTATION NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Alliance Cancer Specialists,

Horsham, Pennsylvania, 19044, United States
CHRU of Lille

Lille, 59037, France
CHU de Liège

Liège, 4000, Belgium
Cleveland Clinic Taussig Cancer Center

Cleveland, Ohio, 44195, United States
Consultants in Medical Oncology & Hematology

Broomall, Pennsylvania, 19008, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Erasmus MC

Rotterdam, 3015 GD, Netherlands
Georgetown University Medical Center

Washington D.C., District of Columbia, 20007, United States
Henry Ford Health System

Detroit, Michigan, 48202, United States
Hospital General Universitario Gregorio Marañón

Madrid, 28007, Spain
Hospital Teresa Herrera (C.H.U.A.C)

A Coruña, 15006, Spain
Hospital Universitario Fundación Jiménez Díaz

Madrid, 28040, Spain
Hospital Universitario Virgen De La Victoria

Málaga, 29010, Spain
Hospital Universitario Virgen de la Macarena

Seville, 41009, Spain
Hôpital Cochin

Paris, 75014, France
Hôpital Foch

Suresnes, 92150, France
Illinois Cancer Specialists

Arlington Heights, Illinois, 60005, United States
Leids Universitair Medisch Centrum

Leiden, 2333 ZA, Netherlands
Maryland Oncology & Hematology, P.A.

Rockville, Maryland, 20850, United States
MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute,

Washington D.C., District of Columbia, 20010, United States
Minnesota Oncology Hematology, P.A

Woodbury, Minnesota, 55125, United States
Northwest Cancer Specialists

Vancouver, Washington, 98684, United States
Ohio State University Brain and Spine Hospital

Columbus, Ohio, 43210, United States
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

Blacksburg, Virginia, 24060, United States
Rocky Mountain Cancer Center, LLP

Boulder, Colorado, 80303, United States
Royal Marsden Hospital

London, SW3 6JJ, United Kingdom
Royal Marsden Hospital

Sutton, SM2 5PT, United Kingdom
Texas Oncology

Austin, Texas, 78731, United States
Texas Oncology

Longview, Texas, 75601, United States
Texas Oncology - Fort Worth Cancer Center

Fort Worth, Texas, 76104, United States
University Hospital Gent

Ghent, 9000, Belgium
University of Leicester

Leicester, LE2 7LX, United Kingdom
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States
Virginia Cancer Specialists, PC

Fairfax, Virginia, 22031, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.